Tumour-suppressor protein p300 can turn into an oncogene
Discovered through first 3D structure of protein’s active core
Means the protein could be a viable drug target
Like a fireman who becomes an arsonist, a protein that prevents cells becoming cancerous can also cause tumours, scientists at the European Molecular Biology Laboratory (EMBL) in Grenoble, France, have discovered. The finding, published today in Nature Structural and Molecular Biology, stems from the first 3D structure of the protein’s active core, and opens up new avenues for drug design.
“Everybody thought this protein was a tumour-suppressor,” says Daniel Panne, who led the work, “but we’ve found that some mutations make it an oncogene – a gene that turns the cell cancerous – which actually makes it a viable drug target.”
Surprisingly, the finding reveals that mutations to this protein that have been linked to cancer can act in two different ways. As expected, some mutations make this ‘fireman’ protein – known as p300 – unable to put out the fire: they cause it to malfunction and lose control over other genes, thwarting its tumour-suppressor role. But, as Panne and colleagues discovered, some cancer-linked mutations actually make p300 into an arsonist: they make it hyperactive, turning it into an oncogene. Which mutations are which? The secret lies in an unexpected piece of the puzzle.
In this study, Panne and colleagues determined the structure of the whole of the protein’s active core – the part that physically interacts with genetic material to control genes – for the first time. They found that this 3D puzzle had one more piece than expected. p300 has a groove that it uses to slot onto the cell’s genetic material to activate or inactivate genes, and the EMBL scientists found that, sitting on top of that groove like a lid, was a piece no-one knew this protein had. This ‘lid’ is like a built-in self-control mechanism. It determines whether the protein can slot onto genetic material or not: for p300 to do its job, it has to open the lid. But if a mutation interferes with the lid, keeping it permanently open, the protein will go into over-drive, and the resulting uncontrolled gene activity can lead to cancer.
Tumours caused by these hyper-activating mutations could potentially be fought by drugs that inhibit p300. So, armed with the knowledge of the protein’s structure, the EMBL scientists now plan to investigate how to thwart p300 when it goes from fireman to arsonist.
Delvecchio, M., Gaucher, J., Aguilar-Gurrieri, C., Ortega, E. & Panne, D. Structure of the catalytic core of p300 and implications for chromatin targeting and HAT regulation. Published online in Nature Structural & Molecular Biology on 11 August 2013. DOI: 10.1038/nsmb.2642.
CBP and p300 are histone acetyltransferases (HAT) that associate with and acetylate transcriptional regulators and chromatin. Mutations in the catalytic ‘core’ are linked to genetic disorders, including cancer. Here we present the 2.8 Å crystal structure of the catalytic core of human p300 containing its Bromodomain, the CH2 region and HAT domain. The structure reveals that the CH2 region contains a discontinuous PHD domain which is interrupted by a RING domain. The Bromodomain, PHD, RING and HAT domains adopt an assembled configuration with the RING domain positioned over the HAT substrate binding pocket. Disease mutations that disrupt RING attachment led to upregulation of HAT activity, revealing an auto-inhibitory role for this domain. The structure provides a starting point for understanding how chromatin substrate targeting and HAT regulation are coupled and why mutations in the core lead to dysregulation of p300.
Sonia Furtado Neves
EMBL Press Officer, Meyerhofstraße 1, 69117 Heidelberg, Germany
|Tel:||+49 6221 387-8263|